CoChat

Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure

Masoudi, Frederick A., Wang, Yongfei, Inzucchi, Silvio E., Setaro, John F., Havranek, Edward P., Foody, JoAnne M., Krumholz, Harlan M. · 2003 · JAMA
Cited by 133

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

CONTEXT: According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure. Little is known about patterns of use of these antihyperglycemic drugs in diabetic patients with heart failure. OBJECTIVE: To determine the proportions of patients hospitalized with heart failure and concomitant diabetes treated with metformin or thiazolidinediones. DESIGN: Serial cross-sectional measurements using data from retrospective medical record abstraction. SETTING: Nongovernmental acute care hospitals in the United States. PATIENTS: Two nationally representative samples of Medicare beneficiaries hospitalized with the primary diagnosis of heart failure and concomitant diabetes between April 1998 and March 1999 and between July 2000 and June 2001. MAIN OUTCOME MEASURES: The prescription of either metformin or a thiazolidinedione at hospital discharge. RESULTS: In the 1998-1999 sample (n = 12 505), 7.1% of patients were discharged with a prescription for metformin, 7.2% with a prescription for a thiazolidinedione, and 13.5% with a prescription for either drug. In the 2000-2001 sample (n = 13 158), metformin use increased to 11.2%, thiazolidinedione use to 16.1%, and use of either drug to 24.4% (P<.001 for all comparisons). Similar increases were seen among patients of all age groups, all races, and both sexes. CONCLUSIONS: The use of metformin and thiazolidinediones is common and has increased rapidly in Medicare beneficiaries with diabetes and heart failure in direct contrast with explicit warnings against this practice by the Food and Drug Administration. Further studies to establish the safety and effectiveness of this practice are needed to ensure optimal care of patients with diabetes and heart failure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.290.1.81

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 133

Metadata

Authors
Masoudi, F. A., Wang, Y., Inzucchi, S. E., Setaro, J. F., Havranek, E. P., Foody, J. M., & Krumholz, H. M.
Venue
JAMA
Published
2003-07-02
Volume
290
Issue
1
Pages
81
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2019007750
Cited by
133
References
2
FWCI
10.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure. https://app.cochat.ai/papers/10.1001/jama.290.1.81
The paper
Masoudi, F. A., Wang, Y., Inzucchi, S. E., Setaro, J. F., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2003). Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure. JAMA. https://doi.org/10.1001/jama.290.1.81

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.